Colorectal cancer remains a significant public health concern in the United States, currently ranking as the second deadliest form of cancer nationwide. The American Cancer Society estimates that over 150,000 new cases will be diagnosed this year alone, with approximately 53,000 expected deaths. Despite advancements in screening and treatment, a troubling rise in cases among younger adults has prompted new research into effective interventions—both pharmaceutical and lifestyle-based.
A landmark clinical study, published in the New England Journal of Medicine and unveiled at the annual American Society of Clinical Oncology (ASCO) conference, has revealed that structured physical activity can have a profound effect on survival rates for colon cancer patients. The research tracked around 900 individuals who had completed chemotherapy between 2009 and 2024. Participants were split into two groups: one received a health booklet promoting good nutrition and exercise, while the other was paired with a physical activity coach for a three-year personalized program.
The results were striking. Patients who worked with a coach had a 28% lower risk of cancer recurrence or the development of new tumors. Their five-year disease-free survival rate was 80%, compared to 74% in the booklet-only group. This means one out of every 16 participants in the coached group avoided further cancer diagnoses.
Lead researcher Dr. Christopher Booth emphasized the importance of incorporating physical activity into treatment plans, stating that the benefits rival those of many established cancer medications. Though the biological mechanisms remain under investigation, reduced inflammation is suspected to play a major role.
Another promising study presented at ASCO examined the effect of diet and inflammation on stage 3 colon cancer patients. Those who consumed anti-inflammatory foods such as leafy greens, tea, and coffee—combined with higher levels of physical activity—experienced a 63% reduction in mortality risk compared to individuals whose diets included processed meats, refined grains, and sugary beverages.
According to lead author Dr. Sara Char from Dana-Farber Cancer Institute, this reinforces the critical role of environmental and lifestyle factors in cancer development and outcomes, especially given the growing incidence in adults under 50.
Researchers believe these findings are not only medically significant but also empowering. Patients often seek tangible ways to improve their outcomes, and tailored lifestyle interventions offer a proactive, sustainable path forward. Dr. Booth noted that most participants achieved the recommended activity level—an hour of brisk walking three to four times a week—making the approach both accessible and effective.
In addition to lifestyle strategies, pharmaceutical innovation is also moving forward. Pfizer introduced encouraging data on its drug Braftovi, used in combination with chemotherapy and an antibody agent, for treating advanced colorectal cancer. The regimen doubled patients’ survival time from 15 to 30 months on average. Braftovi targets a genetic mutation that promotes abnormal cell growth, and the company plans to expand its FDA-approved usage based on this research.
Together, these developments highlight a multi-faceted approach to tackling colorectal cancer—one that combines science, lifestyle, and patient empowerment for better outcomes.
The United States has removed its bombers from a British military base that has played…
North Korea fired two short-range ballistic missiles toward the East Sea on September 20, according…
The United States is experiencing its most serious measles surge in decades, with thousands of…
US businesses are once again dealing with serious disruptions across the supply chain, but the…
The debate over AI safety concerns is becoming increasingly prominent in Washington as President…
Twenty-five years after the September 11 attacks, the health consequences for people exposed to the…